Ulrich Koenig

Ulrich Koenig

Auto-generated profile, based on publicly available information

Ulrich Koenig

Institute of Musculoskeletal Medicine, Dept. Molecular Medicine, University Hospital Münster, Westfälische Wilhelms-Universität Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2007 in Genes & Development
Verified
Journal Article
Open access
PDF file
DODónal O’cArroll
Dónal O’cArroll
IMIngrid Mecklenbrauker
Ingrid Mecklenbrauker
PDPartha Pratim Das
Partha Pratim Das
ASAngela Santana
Angela Santana
UKUlrich Koenig
Ulrich Koenig
ATAlexander Tarakhovsky
Alexander Tarakhovsky
Binding of microRNA (miRNA) to mRNA within the RNA-induced silencing complex (RISC) leads to either translational inhibition or to destruction of the target mRNA. Both of these functions are executed by Argonaute 2 (Ago2). Using hematopoiesis in mice as a model system to study the physiological function of Ago2 in vivo, we found that Ago2 controls early development of lymphoid and erythroid cells. We show that the unique and defining feature of Ago2, the Slicer endonuclease activity, is dispensable for hematopoiesis. Instead, we identified Ago2 as a key regulator of miRNA homeostasis. Deficiency in Ago2 impairs miRNA biogenesis from precursor-miRNAs followed by a reduction in miRNA expression levels. Collectively, our data identify Ago2 as a highly specialized member of the Argonaute family with an essential nonredundant Slicer-independent function within the mammalian miRNA pathway.

1 May 2002 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HFHeinz Fischer
Heinz Fischer
UKUlrich Koenig
Ulrich Koenig
LELeopold Eckhart
Leopold Eckhart
ETErwin Tschachler
Erwin Tschachler

1 February 2004 in Cancer Research
Verified
Journal Article
Closed access
SAStefan Amatschek
Stefan Amatschek
UKUlrich Koenig
Ulrich Koenig
HAHerbert Auer
Herbert Auer
PSPeter Steinlein
Peter Steinlein
MPMargit Pacher
Margit Pacher
WSWolfgang Sommergruber
Wolfgang Sommergruber
With the objective of discovering novel putative intervention sites for anticancer therapy, we compared transcriptional profiles of breast cancer, lung squamous cell cancer (LSCC), lung adenocarcinoma (LAC), and renal cell cancer (RCC). Each of these tumor types still needs improvement in medical treatment. Our intention was to search for genes not only highly expressed in the majority of patient samples but which also exhibit very low or even absence of expression in a comprehensive panel of 16 critical (vital) normal tissues. To achieve this goal, we combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarrays. Seven subtractive libraries consisting of ∼9250 clones were established and enriched for tumor-specific transcripts. These clones, together with ∼1750 additional tumor-relevant genes, were used for cDNA microarray preparation. Hybridizations were performed using a pool of 16 critical normal tissues as a reference in all experiments. In total, we analyzed 20 samples of breast cancer, 11 of LSCC, 11 of LAC, and 8 of RCC. To select for genes with low or even no expression in normal tissues, expression profiles of 22 different normal tissues were additionally analyzed. Importantly, this tissue-wide expression profiling allowed us to eliminate genes, which exhibit also high expression in normal tissues. Similarly, expression signatures of genes, which are derived from infiltrating cells of the immune system, were eliminated as well. Cluster analysis resulted in the identification of 527 expressed sequence tags specifically up-regulated in these tumors. Gene-wise hierarchical clustering of these clones clearly separated the different tumor types with RCC exhibiting the most homogenous and LAC the most diverse expression profile. In addition to already known tumor-associated genes, the majority of identified genes have not yet been brought into context with tumorigenesis such as genes involved in bone matrix mineralization (OSN, OPN, and OSF-2) in lung, breast, and kidney cancer or genes controlling Ca2+ homeostasis (RCN1,CALCA, S100 protein family). EGLN3, which recently has been shown to be involved in regulation of hypoxia-inducible factor, was found to be highly up-regulated in all RCCs and in half of the LSCCs analyzed. Furthermore, 42 genes, the expression level of which correlated with the overall survival of breast cancer patients, were identified. The gene dendogram clearly separates two groups of genes, those up-regulated such as cyclin B1, TGF-β3, B-Myb, Erg2, VCAM-1, and CD44 and those down-regulated such as MIG-6, Esp15, and CAK in patients with short survival time.

1 June 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
YZYi Zhao
Yi Zhao
CZCheng-Feng Zhang
Cheng-Feng Zhang
HRHeidemarie Rossiter
Heidemarie Rossiter
LELeopold Eckhart
Leopold Eckhart
UKUlrich König
Ulrich König
FGFlorian Gruber
Florian Gruber

16 March 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CWCorinna Wehmeyer
Corinna Wehmeyer
SFSvetlana Frank
Svetlana Frank
DBDenise Beckmann
Denise Beckmann
Martin BöttcherMartin Böttcher
Martin Böttcher
CCChristoph Cromme
Christoph Cromme
BDBerno Dankbar
Berno Dankbar
Sclerostin, an inhibitor of the Wnt/β-catenin pathway, has anti-anabolic effects on bone formation by negatively regulating osteoblast differentiation. Mutations in the human sclerostin gene (SOST) lead to sclerosteosis with progressive skeletal overgrowth, whereas sclerostin-deficient (Sost−/−) mice exhibit increased bone mass and strength. Therefore, antibody-mediated inhibition of sclerostin is currently being clinically evaluated for the treatment of postmenopausal osteoporosis in humans. We report that in chronic TNFα (tumor necrosis factor α)–dependent arthritis, fibroblast-like synoviocytes constitute a major source of sclerostin and that either the lack of sclerostin or its antibody-mediated inhibition leads to an acceleration of rheumatoid arthritis (RA)–like disease in human TNFα transgenic (hTNFtg) mice with enhanced pannus formation and joint destruction. Inhibition of sclerostin also failed to improve clinical signs and joint destruction in the partially TNFα-dependent glucose-6-phosphate isomerase–induced arthritis mouse model, but ameliorated disease severity in K/BxN serum transfer–induced arthritis mouse model, which is independent of TNF receptor signaling, thus suggesting a specific role for sclerostin in TNFα signaling. Sclerostin effectively blocked TNFα- but not interleukin-1–induced activation of p38, a key step in arthritis development, pointing to a previously unrealized protective role of sclerostin in TNF-mediated chronic inflammation. The possibility of anti-sclerostin antibody treatment worsening clinical RA outcome under chronic TNFα-dependent inflammatory conditions in mice means that caution should be taken both when considering such treatment for inflammatory bone loss in RA and when using anti-sclerostin antibodies in patients with TNFα-dependent comorbidities.

1 May 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
CZCheng-Feng Zhang
Cheng-Feng Zhang
FGFlorian Gruber
Florian Gruber
CNChunya Ni
Chunya Ni
Michael MildnerMichael Mildner
Michael Mildner
UKUlrich Koenig
Ulrich Koenig
ETErwin Tschachler
Erwin Tschachler